Medicines & Healthcare products Regulatory Agency



Influenza Reagent Influenza Virus Infectious A/South Australia/55/2014 NIBSC code: 14/226 Instructions for use (Version 2.0, Dated 22/03/2016)

1. INTENDED USE

Reagent 14/226 is prepared from A/South Australia/55/2014 which was processed for freeze drying in 250 µl volumes as described by Campbell, PJ, Journal of Biological Standardisation, 1974, 2, 249-267. The known passage history of A/South Australia/55/2014 is attached

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material

4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains 250µl (nominal) of infectious influenza virus as freeze dried allantoic fluid from embryonated SPF hen's eggs.

5. STORAGE

Store in the dark at -20°C or below

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

Reconstitute the contents of one ampoule of reagent with 250μ I of sterile distilled water. Leave for a minimum of 5 minutes before use to allow for complete solution of freeze dried material. A range of dilutions (e.g. 10^{-3} to 10^{-5}) should be made in a suitable medium for initial cutivation.

8. STABILITY

Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

NA

10. ACKNOWLEDGEMENTS

NA

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctlm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties					
Physical appearance:			Corrosive:	No	
White powder Stable:	Yes		Oxidising:	No	
Hygroscopic:	No		Irritant:	No	
Flammable: No			caution, Section 2		
Other (specify): Live influenza					
	Taviaa	Iogia	al proportion		
Toxicological properties					
Effects of inhalation:		Likelihood of influenza virus infection			
Effects of ingestion:		Not established, avoid ingestion			
Effects of skin absorption:		Not established, avoid contact with skin			
Suggested First Aid					
Inhalation:	halation: Seek medica				
Ingestion:	stion: Seek medical advice				
Contact with eyes: Wash with copious amounts of water. Seek				s of water. Seek	
medical advice					
Contact with skin:	Wash tl	horou	ighly with water		
Action on Spillage and Method of Disposal					
Spillage of contents wetted with a virucio				rbent material appropriate virucidal	
agent followed by w	ater.				
Absorbent materials used to treat spillage should be treated as					

Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon

Medicines & Healthcare products Regulatory Agency



request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying. Net weight: NA

Toxicity Statement: Non-toxic Veterinary certificate or other statement if applicable.

Attached: No

Derivation of A/South Australia/55/2014

Passage	Lot	Laboratory
E1-E4		unknown
E5	14070411	VIDRL, Melbourne, Australia
E6	39670	NIBSC, Hertfordshire, UK

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus is available on GISAID with the accession number EPI_ISL_207649

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory